Strong topline growth masks battery losses; execution risk on capex delays
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Fluoropolymer beat 17–20% guidance with 22% delivery. Battery materials on track for 3-digit Q4 but currently loss-making. Capex target INR 3,100 Cr slipping due to Oman delay.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong topline growth (45.5% YoY revenue, 34.1% PAT) and fluoropolymer beat guidance (22% vs 17–20%), but battery materials losing ₹~50 Cr currently despite commercial ramp expected Q4 FY27. Capex execution risk: Oman project delayed 1–1.5 quarters, LFP capacity expansion pushed. Margin stable at 27% EBITDA but flat sequentially.
₹1760 Cr
Revenue · +45.5% YoY₹240 Cr
Reported PAT · +34.1% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Fluoropolymer 22% YoY growth, beat 17–20% guidance
METINR 931 Cr vs INR 764 Cr YoY (22% confirmed). Guidance reaffirmed at 17–20%, so beat on delivery.
Chemical segment PAT 46% YoY growth to INR 290 Cr
METConsolidated PAT INR 240 Cr; chemical segment INR 290 Cr implies battery segment loss ~INR 50 Cr. Claim checks against chemical segment, not consolidated.
EBITDA margin 27%, resilient despite market environment
METEBITDA INR 473 Cr on revenue INR 1,760 Cr = 26.9% OPM; call states 27% EBITDA margin. Consistent.
Battery materials ramp-up to 3-digit revenue by Q4 FY27
METLiPF6 sales to 5 major global electrolyte players, commercial supplies Q4 FY27. Currently in loss (INR ~50 Cr negative). On track, not yet realized.
R-32 utilization to reach full capacity by Q3 FY27
METMD: 'quarter going on, we'll probably reach the full utilization.' Fluorochemicals revenue up 135% YoY on R-32 demand. Directionally supported but not yet at full.
Capex on track: INR 3,100 Cr FY27 spend
OVERSTATEDMD disclosed Oman project delayed 1–1.5 quarters, LFP capacity expansion pushed, some delay to Q4 FY27 start. Spend overall tracking but slower than initially planned.
Earnings quality
What changed since the last call
Fluoropolymer delivery beats prior guidance
UpgradeQ2 delivered 22% YoY (INR 931 Cr) vs reaffirmed 17–20% guidance. Growth momentum accelerating in high-value applications (automotive FKM, PSA, data centers).
Battery segment still loss-making, not yet profitable
NeutralChemical segment PAT +46% YoY to INR 290 Cr, but battery segment ~INR 50 Cr loss. Expected; on track to 3-digit Q4 revenue per guidance.
Capex execution slips; Oman project delayed
DowngradeINR 2,100 Cr of ₹3,100 Cr battery capex now pushed 1–1.5 quarters. Project was planned to India but hold taken; LFP additional capacity also deferred.
Bulk Chemicals revenue down 5% YoY
DowngradeINR 151 Cr vs INR 158 Cr YoY (Q2 FY26), decline driven by caustic soda price collapse and higher captive consumption for R-32 production.
The Q&A
Analysts pressed hard on capex execution (Ankur, Akash, Archit on delays, funding, anode timing, cathode sourcing). MD candid about Oman delay 1–1.5Q, LFP capacity deferral, anode project 'not a priority right now'. On pricing (Sanjesh on LiPF6 China deflation), MD acknowledged lithium-linked drop but held margin defense. On volume binding (Hansal), disclosed multi-year contracts with volume binding, supporting long-term visibility. Overall, analysts held management to account; management held firm on guidance.
PTFE dry electrode adoption — Ketan Gandhi, Gandhi Securities
AnsweredPTFE grades advanced-stage commercial trial with multiple companies. MD: 'very optimistic,' demand for PTFE will pick up as battery OEMs move to dry electrode systems. Several grades in advanced trial, no solvent recovery/environmental upside.
Janiadara plant scope and capex — Ketan Gandhi, Gandhi Securities
DodgedMD declined to name specific chemicals (WF6, CaF6, NF3, F2, etc.). 'Very early stage of discussion, will share in next quarters.' Strong government push on sector, significant opportunity with fluorochemical expertise.
R-32 capacity utilization timeline — Sanjesh Jain, ICICI Securities
AnsweredMD: 'This quarter going on, we'll probably reach the full utilization.' R-134A production commences Q4 FY27. Capex on track for both.
LiPF6 pricing pressure and sustainability — Sanjesh Jain, ICICI Securities
AnsweredMD: 'Lithium price is −what LiPF6 is dropping as a result. Lithium pricing falloff.' Margin protected via lithium pass-through formula with customers. Adder-based pricing maintains spread.
LFP capacity expansion and timing — Sanjesh Jain, ICICI Securities
PartialMD: 'Next financial year, capacity and what we had planned, we'll see impact of that in next 2 to 3 quarters.' Ramp-up due to qualification, order pipeline strong. Expanded capacity + existing LiPF6 plant full swing by Q1 FY28.
Battery capex breakdown and execution — Ankur Periwal, Axis Capital
AnsweredINR 800 Cr for fluoropolymer/chemicals mostly done. INR 2,100 Cr battery: INR 900 Cr for LiPF6 on track, INR 1,200 Cr for salt/electrolyte/anode/backward integration. Oman capex on hold, capacity to India instead. Delays expected.
Anode project timeline and capex — Archit Joshi, Nuvama
DodgedMD: 'Anode will come subsequent to LFP. Right now, focus is LFP, electrolyte, salt.' Anode capex deferred; not a priority. May start late next FY depending on market. No specific timeline given.
Electrolyte demand ramp India — Archit Joshi, Nuvama
AnsweredMD: 'Middle of next financial year, we expect domestic market to slowly ramp up.' Electrolyte revenues likely mid-FY28 onwards. Current battery production in India 'very, very low' on gigawatt hour basis.
FY28 battery revenue scale and composition — Rohit Nagraj, 360 ONE Capital
PartialMD: 'Initially, a big part of revenue will come from salt. LFP larger capacity towards Q3. Then electrolyte.' FY28 ramp tied to capacity commissioning. Exports first, domestic slow ramp middle of FY28.
LiPF6 customer volume binding — Hansal Thacker, Lalkar Securities
AnsweredRajiv Rao: 'Annual contracts or longer. Volume bound for at least next financial year, some longer.' Long-term contracts with major electrolyte players. Limited spot exposure.
Guidance
Fluoropolymer 17–20% annual growth (reaffirmed)
HighQ2 delivered 22%, exceeding range. Management confident in sustained high-value application traction.
Battery materials 3-digit revenue by Q4 FY27
MediumLiPF6 sales ramping, PVDF/PTFE in qualification. Timing tied to customer approvals and capex execution.
EBITDA margin ~27% (reaffirmed)
HighResilience demonstrated in Q2; margin protected despite input cost volatility (lithium pass-through, caustic soda deflation).
FY27 capex INR 3,100 Cr (INR 2,300 Cr battery/EV, INR 800 Cr chemicals)
MediumOn track but slipping. Oman project delayed 1–1.5 quarters; capacity shifted to India. LFP expansion deferred. Expected to slip into FY28.
Multi-year capex target INR 6,000 Cr over next few years
LowAspirational; tied to battery commercialization pace and approval timelines. No specific horizon given.
Risks the call surfaced
Capex execution delay
HighOman LFP project on hold, shifted to India; 1–1.5 quarter delay. LFP expansion timeline pushed back. Execution risk on multi-year INR 6,000 Cr capex plan.
Battery segment profitability timeline
HighBattery segment currently loss-making (~INR 50 Cr in Q2). Profitability depends on customer qualification timelines, electrolyte demand ramp in India (expected mid-FY28), and volume scale. Execution heavily dependent on OEM approvals.
LiPF6 pricing pressure from China
MediumLiPF6 prices down 33% in one month (INR 150K → INR 100K/unit) due to Chinese competition. Margin protected via lithium pass-through, but tail risk if volumes don't scale or lithium prices stabilize while competitive pressure persists.
Domestic battery demand uncertainty
MediumElectrolyte ramp in India expected mid-FY28, not FY27. Current battery production in India 'very, very low' on gigawatt-hour basis. Timing of domestic EV/battery adoption uncertain; affects ramp-up pace and capex utilization.
Bulk Chemicals margin pressure
LowBulk Chemicals down 5% YoY to INR 151 Cr. Caustic soda price collapse driving decline; higher captive R-32 consumption reducing available volumes for external sale. Margin dependent on R-32 ramp and caustic soda price recovery.
Management
Score 7/10. Clear and transparent. MD provided detailed segment-wise breakdowns, acknowledged capex delays (Oman), explained pricing dynamics (lithium pass-through). Some deflection on Janiadara chemicals and anode project timing, citing early-stage discussions. Mixed. Fluoropolymer beat 17–20% guidance (22% delivered). Battery materials on track for Q4 3-digit revenue but currently loss-making. Capex slipped: Oman delayed 1–1.5 quarters. EBITDA margin at 27% is solid.
1 · Q3 FY27 (Oct–Dec 2026)
R-32 utilization at full capacity; R-134A production commences
2 · Q4 FY27 (Jan–Mar 2027)
Battery materials 3-digit revenue realization; LiPF6 commercial supplies begin
3 · H2 FY28 (Jul 2027+)
Domestic electrolyte demand ramp-up; LFP larger capacity utilization begins
Margin stable at 27% EBITDA but flat sequentially.
Growth beats fluoropolymer guide, but battery losses and capex delays mask the picture
Revenue and profit both rose 45% and 34% YoY, and fluoropolymer beat guidance by 2 percentage points. But battery materials are still losing ₹50 crore and capex execution is already slipping.
₹1,760 Cr
+45.5% YoY; +10.8% QoQ
₹240 Cr
+34.1% YoY; +9.6% QoQ
₹290 Cr
+46% YoY
~₹50 Cr
in loss phase
The headline reads strong: revenue up 45.5% YoY to ₹1,760 crore, profit up 34.1% to ₹240 crore. Fluoropolymer beat its own guidance, delivering 22% growth versus the 17–20% target. But dig deeper and the earnings mask a buried story. The chemical segment's 46% PAT growth is real. The consolidated 34% is held back entirely by battery losses. Battery materials are currently burning ₹~50 crore — the gap between chemical segment profit (₹290 crore) and consolidated profit (₹240 crore). And the capex plan that's supposed to unlock battery scale is already slipping: the Oman project delayed 1–1.5 quarters, LFP expansion deferred, anode deprioritized. For a stock trading near its all-time high and held mostly by promoters and institutions, this is the tension that matters.
Where the growth came from
Fluoropolymer drove the quarter with ₹931 crore, up 22% YoY, momentum accelerating in automotive seals (FKM), polysulfone (PSA), and semiconductors. Fluorochemicals nearly tripled to ₹607 crore on the global shift from R-410A to R-32 refrigerants; management expects full capacity by Q3 FY27 and R-134A production by Q4 FY27. Together they deliver the reported ₹1,723 crore chemical segment revenue and ₹290 crore PAT. The rest is battery materials, currently in loss. LiPF6 has signed 5 major global electrolyte OEMs with multi-year volume binding. PVDF and PTFE grades are in advanced customer trial. The company guidance says 3-digit revenue by Q4 FY27, but the units are not yet commercial. Profitability is expected mid-FY28 after electrolyte ramps in India.
Management's core claims — what holds up
Fluoropolymer 22% beats 17–20% guidance
₹931 Cr vs ₹764 Cr YoY = 22%. Guidance reaffirmed, not raised.
Supported
Chemical segment PAT +46% YoY to ₹290 Cr
Disclosed. Consolidated PAT ₹240 Cr implies battery loss ₹~50 Cr.
Supported
EBITDA margin 27%, resilient
₹473 Cr EBITDA on ₹1,760 Cr revenue = 26.9%. Margin flat YoY and QoQ.
Supported
Battery 3-digit Q4 FY27 revenue on track
LiPF6 in trial with 5 OEMs; commercial supplies expected Q4. Not yet realized.
Supported (not yet achieved)
FY27 capex ₹3,100 Cr on track
Oman delayed 1–1.5 quarters, shifted to India. LFP deferred. Spend tracking into FY28.
Overstated
What changed on this call
Fluoropolymer beat. The 22% growth versus 17–20% signals sustained momentum in high-value applications (automotive, semiconductors, data centers). Management is confident; guidance reaffirmed, not raised. Bulk Chemicals down 5%. Caustic soda prices collapsed globally; higher captive consumption for R-32 production. Temporary. Battery profitability timeline shifted. Still losing ₹~50 crore. Electrolyte ramp in India moved from FY27 to mid-FY28. 3-digit Q4 FY27 revenue expected, but path to positive PAT is now 12+ months away. Capex execution slipping. Oman project on hold, capacity pivoted to India — 1–1.5 quarter delay. LFP expansion deferred. Anode deprioritized ('not a priority right now'). Analysts pressed; management acknowledged delays but held guidance.
Price and market positioning
As of 2026-11-05, the stock trades at ₹4,709.6 — up 61.5% from the 52-week low but 5.0% below its all-time high of ₹4,958.9. It sits above its 20-, 50-, and 200-day moving averages (₹4,414, ₹4,517, ₹3,894), confirming sustained bullish momentum. RSI at 63.3 is neutral (not extended). Volume is normal. Foreign investors hold 4.41% (up 0.13pp QoQ), domestic institutions 13.33% (down 0.16pp), promoters 61.39% (unchanged). This ownership split — promoter-dominated, stable institutions — suggests the stock is held by long-term believers, not momentum traders.
Fluoropolymer beat 17–20% guidance at 22%; high-value segments accelerating
R-32 platform +135% YoY; full utilization expected Q3 FY27
EBITDA margin 27% stable despite input volatility and battery drag
Battery materials signed 5 major global OEMs with volume binding
Battery segment currently ₹~50 Cr loss; profitability deferred to mid-FY28
Capex execution slipping — Oman 1–1.5 Q delay, anode deprioritized
LiPF6 pricing down 33% in one month from China; margin protected by lithium pass-through but volume tail risk
Bulk Chemicals down 5% YoY; caustic soda deflation is temporary headwind
Risks — ranked by holder concern
Capex execution delays compound
HighOman on hold 1–1.5 quarters, shifted to India. LFP deferred. Anode deprioritized. ₹3,100 Cr FY27 target slipping into FY28. Cascading delays cascade — if the sequence breaks, multi-year ₹6,000 Cr capex becomes unachievable at guided pace.
Battery profitability timeline extends
HighCurrently ₹~50 Cr loss. Electrolyte ramp pushed to mid-FY28. If domestic EV adoption in India is slower or customer qualifications extend, profitability slips another 1–2 quarters. Further depresses consolidated earnings and capex ROI.
LiPF6 pricing deflation from China persists
MediumPrices fell 33% in one month (₹150K to ₹100K per unit). Lithium pass-through protects margin, but tail risk if prices floor below cost or if customers switch suppliers. Sustained deflation erodes volume confidence.
Domestic battery demand ramps slower than mid-FY28
MediumCurrent Indian battery production 'very, very low' on GWh basis. Electrolyte ramp depends on OEM plant stabilization and customer timelines. If domestic EV cycle is slower, capex utilization will be lower and profitability delayed further.
Bulk Chemicals margin pressure persists
LowDown 5% YoY. Caustic soda deflation and captive R-32 consumption. Temporary; will recover if R-32 ramp stabilizes and caustic prices normalize. Low urgency if core segments hold.
1 · R-32 utilization Q3 FY27
Management guided full capacity by Q3 FY27. If delivered, it confirms refrigerant upside and stabilizes bulk chemicals margin. Watch the Q3 press release.
2 · Battery 3-digit Q4 FY27 revenue
Guided for Q4 FY27 (Jan–Mar 2027). This is the proof point that LiPF6 trials have converted to commercial sales. If it happens, battery bull case resets. If it slips, credibility erodes.
3 · Capex execution and FY28 spend
Next quarterly call will show whether India-based capex shift is real and on schedule, or whether 1–1.5 quarter delay becomes 2+ quarters. This resolves multi-year capex plan viability.
Gujarat Fluorochemicals is a well-positioned chemical franchise with genuine long-term optionality in battery materials. This quarter confirms fluoropolymer acceleration and R-32 platform strength. It also confirms that battery is unprofitable, capex execution is slipping, and the timeline to guided profitability is narrowing. The stock trades 5% below its all-time high, held by promoters and institutions, and sits above all moving averages. The market is still optimistic on battery upside — and the contracts are real. But holders should watch three things closely: the rate at which capex delays accumulate, whether battery profitability actually narrows the loss in Q3–Q4, and whether management's Q4 3-digit revenue and mid-FY28 electrolyte ramp actually materialize. On that clarity, this Hold will either firm into a Buy or slip into a Sell. The single number to track from here is battery segment loss — not when it turns positive, but by how much it shrinks over the next two quarters.
Can FLUOROCHEM recover the margin miss from Q1?
Gujarat Fluorochemicals reports Q2 FY27 on Nov 3 with the Street watching volumes and profit leverage after Q1's revenue beat masked a significant PAT miss. Current price weakness — 14% off ATH — is betting that specialty chemicals and EV-adjacency growth can't offset cost pressures and expanding EV losses.
The Setup: Q1 Exposed the Margin Gap
Gujarat Fluorochemicals shocked the Street in August with a revenue beat but a dramatic PAT miss. Consolidated revenue of ₹1,588 Cr crushed expectations (Street preview: ₹1,395 Cr; +24% YoY growth), but net profit of ₹219 Cr fell short of the Street's ₹276 Cr view by ₹57 Cr—a 21% shortfall on profit despite a 14% revenue beat. The culprit: cost inflation in raw materials and energy, coupled with widening losses in the company's EV-related subsidiaries. This Q2 is all about whether management can recover that leverage.
~₹1,500–1,550 Cr
On-plan run-rate: Q1 was ₹1,588 Cr; growth trajectory suggests steady or slight sequential moderation with YoY growth of 20–25%.
~₹200–230 Cr
Recovery threshold: Q1 was ₹219 Cr. Street will scrutinize margin % and whether cost pressures ease or EV losses stabilize. A PAT miss of >₹30 Cr again would signal structural margin headwinds.
~20–22%
Q1 implied margin pressure despite volume growth. Watch for pass-through of input costs to customers or operational improvements.
Focus item
Expanding losses are a drag on consolidated PAT. Q2 disclosure on this sub will shape FY27 guidance credibility.
A strong Q2 would show: (1) revenue on-plan or ahead, (2) PAT recovery to ₹225–250 Cr range (i.e., margin recovery YoY and QoQ), (3) EBITDA margin stabilization above 21%, and (4) EV losses either static or itemized as a temporary investment phase. A weak Q2 would repeat Q1's pattern: revenue strength masking profit miss, EV losses expanding, and forward guidance unclear on leverage recovery. Anything below ₹210 Cr PAT would signal that cost inflation is structural, not transient.
On Track for FY27 Guidance?
The company has not issued explicit quarterly or full-year PAT guidance, but analyst consensus for FY27 points to EPS growth of ~59% and revenue growth of ~32.5%. For that to hold, H2 would need stronger profitability than H1 is showing. Q1 PAT of ₹219 Cr annualizes to ~₹876 Cr at that run-rate—below the 59% EPS growth implied. This means either Q2–Q4 margins must improve materially, or the 59% EPS growth implies a lower earnings base than Q1 suggests. Investors should press management on whether the PAT miss in Q1 was one-time (input inflation easing, EV subs stabilizing) or the new normal (requiring margin expansion elsewhere). The price is 14% off ATH despite analyst targets of ₹4,860, suggesting the market is skeptical of that leverage recovery.
What the Street Says
Since Last Quarter: Filings & Corporate Actions
Aug 27, 2026
FY26 final dividend declared; record date Sep 17. Routine shareholder return; no strategic signal.
Dividend: Final ₹3/share
Aug 27, 2026
8th AGM held Sep 24. Board re-appointed Dr. Bir Kapoor (Deputy MD) and Niraj Kishore Agnihotri (Whole-time Director). Governance routine; no major leadership change.
AGM & Annual Report (FY26)
Sep 24, 2026
Shareholders approved re-appointment of two key executives. Continuity signal on management.
AGM: Directors re-appointed
Sep 28, 2026
Window closed Oct 1, 2026 for Q2 results announcement. Standard regulatory closure; no insider activity noted.
Trading Window Closure
Oct 26, 2026
Board to convene Nov 3, 2026 to approve Q2 FY27 unaudited financial results. Result day confirmed.
Board Meeting Notice
No major M&A, pledge updates, or regulatory concerns flagged. The Scheme of Arrangement with Inox Leasing (announced in Q1) received BSE/NSE no-objection letters in July—no further update in recent filings, suggesting it is progressing as planned but not material to Q2 guidance. Insider trading window closure on Oct 1 is routine. Overall, the quarter has been quiet on corporate action; the focus is entirely on operational execution.
What to Watch on Result Day (Nov 3)
1 · Profit recovery & margin narrative
Did PAT improve QoQ or YoY? Is it ≥₹220 Cr (recovery signal) or <₹210 Cr (structural miss)? Listen for management commentary on input-cost trends: are they easing in October–November, or does the company expect ongoing inflation? A credible path to 15%+ PAT margin (vs. implied 14% now) would stabilize sentiment.
2 · EV subsidiary losses & guidance
How much PAT drag from EV-related businesses? Is it being phased out, or is it a long-term investment? If losses >₹20 Cr and no timeline to breakeven, analysts may reduce FY27 EPS estimates. Q2 disclosure (even if unaudited) on this segment is critical to FY27 credibility.
3 · FY27 full-year outlook & management tone
Does management reaffirm the implied 59% EPS growth? Or do they guide more conservatively? Any update on battery-chemicals or fluoropolymer volumes? If H2 visibility is weak or EV losses are expected to widen further, sentiment will sour despite Q1 revenue strength. A timid outlook would likely trigger analyst cuts and renewed price weakness.
FLUOROCHEM is at an inflection. Q1 showed the company can drive volume growth (+24% revenue), but profitability leverage is stuck—a ₹57 Cr PAT miss erased the celebration. The market has noticed: the stock is down 15% from its all-time high despite analyst consensus that EPS should grow 59% this year. That skepticism hinges entirely on Q2. If margins recover and management can credibly map a path to the 59% EPS growth, the analyst consensus target of ₹4,860 becomes plausible. If Q2 repeats Q1's pattern (volume beat, profit miss), expect target cuts and further downside.
Watch three things on Nov 3: (1) did PAT rebound above ₹220 Cr and margins stabilize? (2) are EV losses explained and bounded? (3) does management stand by FY27 guidance with conviction? The answers will reset the narrative from 'growth missed by execution' to either 'margin recovery underway' or 'structural cost pressure.' Current price weakness leaves room for a 15% upside to analyst targets—but Q2 profitability is the gate.
GFL Q2 FY27: Consolidated PAT +42% YoY to ₹240 Cr, margin holds near 27%, tops Street view
PAT +42% YoY · revenue +45.5% · margins compressing · beat vs street
₹1,760 Cr
+45.5% YoY
₹240 Cr
+42% YoY
13.56%
-1.2pp YoY
₹22.11
Gujarat Fluorochemicals' consolidated Q2 FY27 print clears the bar the Street set going in. Revenue came in at ₹1,760 Cr against a pre-result expectation of ₹1,500–1,550 Cr, and consolidated PAT of ₹240 Cr beat the ₹200–230 Cr range analysts had pencilled in (per our pre-result preview, citing S&P Global/TipRanks/SimplyWall.st consensus). The bigger surprise is on margins: EBITDA of ₹473 Cr works out to a 26.9% margin, comfortably above the 20–22% the Street was bracing for after Q1's margin miss, and essentially flat against Q1's 27.0% — so the 'margin recovery' question our preview posed is better read as margin stabilization than a sharp rebound. Consolidated basic EPS was ₹22.11 (standalone ₹28.12).
Q2 FY-2027 vs prior quarters
The headline YoY PAT growth needs a caveat. On a reported basis PAT is up 42% from the year-ago quarter's restated ₹169 Cr; our stored year-ago record of ₹179 Cr (EPS ₹16.31) is the figure as originally reported, before this filing's Note 4 restated it down by ₹10 Cr after the EV Products subsidiary reversed a ₹24 Cr deferred-tax asset and reclassified ₹22 Cr of capital work-in-progress. Against that originally-reported base, YoY PAT growth reads closer to 34%. Either way, growth is driven by the core Chemicals segment, where revenue rose 43% YoY to ₹1,743 Cr and EBITDA to ₹505 Cr; margins there are still down from a year ago (consolidated EBITDA margin 26.9% vs 29.6% in Q2 FY26), consistent with the cost pressure the preview flagged. A new ₹7 Cr fair-value loss on the EV subsidiary's Series A CCPS also sat in this quarter's finance costs — strip it out and PBT would be closer to ₹346 Cr versus the reported ₹339 Cr.
The stock went into the print at ₹4,506.4, up 3.5% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Fluoropolymer 17–20% annual growth reaffirmed (Q1 delivered 15%, mix-driven). Battery materials expected 3-digit revenue by Q4 FY27, significant ramp FY28 onwards. FY27 capex ₹3,100 Cr (₹2,300 Cr EV, ₹800 Cr chemicals) on track; target ₹6,000 Cr over multi-years.
On guidance, the filing doesn't break out fluoropolymer-specific volumes, so the 17–20% annual fluoropolymer growth target reaffirmed at the Q1 call can't be directly graded this quarter. The EV Products segment, management's other guided marker, posted ₹41 Cr of revenue (up from ₹29 Cr in Q1) with the EBITDA loss widening to -₹32 Cr from -₹30 Cr — still well short of the 3-digit-crore quarterly revenue management has guided for Q4 FY27, though two quarters remain. H1 consolidated capex (cash, including CWIP movements) of ₹841 Cr tracks toward but is still well under a third of the ₹3,100 Cr FY27 target (₹2,300 Cr EV, ₹800 Cr chemicals) management laid out, implying a much heavier H2 spend. No management press release or commentary accompanied this filing, so there is no fresh management quote to check against the numbers.
W1
EV Products revenue run-rate vs management's 3-digit-crore (₹100 Cr+) quarterly target for Q4 FY27 (currently ₹41 Cr, up from ₹29 Cr in Q1).
W2
EV Products EBITDA loss trend (-₹32 Cr this quarter, -₹30 Cr in Q1, -₹23 Cr a year ago) — management guides to a 'significant ramp' only from FY28, so losses are expected to keep widening before turning.
W3
FY27 capex pacing against the ₹3,100 Cr guided total (₹2,300 Cr EV Products, ₹800 Cr chemicals) — H1 cash capex (incl. CWIP) was ₹841 Cr, implying a steep H2 ramp to hit the full-year number.